Kinara Vision Technologies
A minimally invasive treatment for angle-closure glaucoma
First-in-class microstent restoring physiological outflow for an underserved patient group.
Investigational device — not approved for clinical use.
Kinara Vision Technologies
First-in-class microstent restoring physiological outflow for an underserved patient group.
Investigational device — not approved for clinical use.
Supported by
The Challenge
Angle-closure glaucoma will affect over 36 million people in Asia by 2040, causing irreversible blindness at three times the rate of open-angle glaucoma. Current devices were not designed for these patients.
Introducing Flostream
Flostream is a microstent that creates an alternative outflow pathway, bypassing the trabecular meshwork and closed angle entirely. It is placed with a single-use deployment system designed for accurate, repeatable delivery.
Why It Matters
Creates access to drainage independent of closed angle, bypassing the obstruction entirely.
A purpose-built, single-use deployer engineered for consistent, tactile-feedback-guided implant placement.
Built to reach a space in the eye inaccessible to existing devices.
Investor Signal
Bench testing, biocompatibility studies, and design verification completed with supportive safety and performance data. Preparing for first-in-human evaluation in Singapore.
Currently raising seed funding to advance toward clinical-stage development.
The team combines medical device engineering with glaucoma surgical practice
Preeti Mohan
CEO, Founder
Singapore Biodesign Fellow
Dr. Bert Wouters
CTO, Co-founder
PhD Microfluidic Engineering
Assoc. Prof. Shamira Perera
Clinical Lead, Co-founder
Head of Glaucoma, Singapore National Eye Centre
Important Information
Flostream is an investigational medical device. Not approved for commercial use in any jurisdiction. Content on this website is provided for informational purposes only and does not constitute medical advice, promotion, or solicitation.